Genmab rises on Phase II daratumumab promise in double refractory myeloma

Shares in Genmab rose by as much as 9% on the morning of 4 February after it announced a nearly 30% overall response rate in a Phase II trial of its anti-CD38 antibody product daratumumab as a monotherapy in double refractory multiple myeloma patients. The product already has a breakthrough therapy designation for this indication.

In the study, conducted by its partner Janssen Biotech (Johnson & Johnson), an Independent Review Committee found that the overall response rate (ORR) was 29.2% in the 16 mg/kg dosing group and the median duration of response was 7.4 months